D. Kerr

发表

Inequalities in breast cancer care and outcome.

R. Sainsbury, M. Richards, M. Richards, 1997, British Journal of Cancer.

Demonstration of stem cell inhibition and myeloprotective effects of SCI/rhMIP1 alpha in vivo.

D. Dunlop, T. Holyoake, E. Wright, 1992, Blood.

Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial

D. Kerr, C. McArdle, R. Stephens, 2003, The Lancet.

Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial

C. McArdle, J. Ledermann, R. James, 2002, The Lancet.

A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer.

D. Rea, D. Richel, C. Punt, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Colorectal cancer in the adjuvant setting: perspectives on treatment and the role of prognostic factors.

R. Labianca, M. Ychou, S. Cascinu, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Regional chemotherapy for inoperable renal carcinoma: a method of targeting therapeutic microspheres to tumour.

C. McArdle, W. Angerson, R. Bessent, 1991, British Journal of Cancer.

Regional chemotherapy for colorectal liver metastases: A phase II evaluation of targeted hepatic arterial 5‐fluorouracil for colorectal liver metastases

D. Kerr, J. Mckillop, D. Kerr, 1990, The British journal of surgery.

Microparticulate drug delivery systems as an adjunct to cancer treatment.

D. Kerr, 1987, Cancer drug delivery.

Intravesical administration of bacillus Calmette-Guérin in patients with recurrent superficial carcinoma of the urinary bladder: report of a prospective, randomized trial.

N. Geller, W. Whitmore, H. Oettgen, 1985, Cancer treatment reports.

Phase I trials of poly(I,C) complexes in advanced cancer.

W. Stewart, H. Oettgen, S. Krown, 1985, Journal of biological response modifiers.

Gene expression in oestrogen-dependent human breast cancer xenograft tumours.

H. J. Evans, D. Carter, C. Steel, 1990, British Journal of Cancer.

Fluid dynamics in man of an intraperitoneal drug delivery solution: 4% icodextrin.

C. Brown, K. Hosie, D. Kerr, 2001, Drug delivery.

Transforming growth factor beta 1 is implicated in the failure of tamoxifen therapy in human breast cancer.

C. Steel, A. Thompson, D. Kerr, 1991, British Journal of Cancer.

Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial

D. Kerr, H. Friess, J. Neoptolemos, 2001, The Lancet.

Gene therapy for colorectal cancer

L. Seymour, F. Maruta, D. Kerr, 2003, British medical bulletin.

Human leukocyte (alpha) interferon in metastatic malignant melanoma: the American Cancer Society phase II trial.

J. Kirkwood, D. Morton, H. Oettgen, 1984, Cancer treatment reports.

The TERT variant rs 2736100 is associated with colorectal cancer risk

L. Lipton, O. Sieber, J. Hopper, 2015 .

The TERT variant rs2736100 is associated with colorectal cancer risk

L. Lipton, D. Kerr, O. Sieber, 2012, British Journal of Cancer.

Cytotoxic‐loaded albumin microspheres: A novel approach to regional chemotherapy

D. Kerr, C. McArdle, J. Mckillop, 1988, The British journal of surgery.

Women's health research at NIEHS.

T. Cooke, C. McArdle, W. Angerson, 1993, British Journal of Cancer.

Is there a relationship between regional microsphere distribution and hepatic arterial blood flow?

James H. Anderson, T. Cooke, C. McArdle, 1992, British Journal of Cancer.

An in vivo assessment of adriamycin-loaded albumin microspheres.

C. McArdle, N. Willmott, D. Kerr, 1992, British Journal of Cancer.

Regional delivery of microspheres to liver metastases: the effects of particle size and concentration on intrahepatic distribution.

T. Cooke, C. McArdle, W. Angerson, 1991, British Journal of Cancer.

The cytostatic effects of alpha-interferon may be mediated by transforming growth factor-beta.

I. Pragnell, S. Cowan, A. Sproul, 1989, Journal of molecular endocrinology.

The pharmacokinetic advantages of isolated limb perfusion with melphalan for malignant melanoma.

G. Burnside, R. Blackie, D. Byrne, 1992, British journal of cancer.

Laboratory of Biochemical Risk Analysis

R. MacKie, G. Burnside, R. Blackie, 1993, British Journal of Cancer.

Melphalan concentration and distribution in the tissues of tumour-bearing limbs treated by isolated limb perfusion.

R. MacKie, G. Burnside, R. Blackie, 1992, European journal of cancer.

Melphalan in Isolated Limb Perfusion for Malignant Melanoma, Bolus or Divided Dose, Tissue Levels, the pH Effect

T. Wheldon, R. MacKie, S. Kaye, 1990 .

Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer.

D. Kerr, T. Powles, G. Rustin, 1992, Oncology.

A feasibility study of roquinimex (Linomide) and alpha interferon in patients with advanced malignant melanoma or renal carcinoma.

D. Jodrell, J. Cassidy, M. Mackean, 1998, British Journal of Cancer.

The isolation and identification of cis-diamminedichloroplatinum (ii)-DNA adducts by anion-exchange HPLC and inductively coupled plasma mass-spectrometry.

D. Bissett, R. Brown, M. Graham, 1993, International journal of oncology.

A pilot study of quinidine and epirubicin in the treatment of advanced breast cancer.

D. Kerr, S. Kaye, S. Kaye, 1990, British Journal of Cancer.

A phase II study of regional 5-fluorouracil infusion with intravenous folinic acid for colorectal liver metastases.

D. Kerr, T. Cooke, C. McArdle, 1994, British Journal of Cancer.